Pharmasset to Present at Two Upcoming Investor Conferences

PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq:
VRUS) announces management will present at the upcoming Citi Fourth Annual
Biotech Day Conference and the Canaccord Adams Hepatitis C Conference. The
Citi conference will be held in New York (April 1), while the Canaccord Adams
conference will be held at the InterContinental The Barclay New York Hotel in
New York City (April 7).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will
provide an overview of the Company at the Citi conference on Wednesday, April
1, 2009 at 4:00 PM (ET) and review the Company's HCV drug pipeline at the
Canaccord Adams conference on Tuesday, April 7, 2009 at 1:30 PM (ET).
To access a simultaneous webcast of Mr. Price's presentations via the
internet, log on to the "Events & Presentations" section of the Investor
Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .
Please connect to the website at least ten minutes prior to the start of the
presentation to ensure adequate time for a reliable connection and any
software download that may be necessary for the webcast.
A replay of the webcast will be available on Pharmasset's website for thirty
days following the conference. The investor presentation will be available for
download in PDF format immediately following the presentation in the "Events &
Presentations" section of the Investor Center on Pharmasset's website at
http://investor.pharmasset.com/events.cfm .

About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus
(HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing four product candidates. Clevudine, for
the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials
for registration in North, Central and South America, Europe, Japan and
Taiwan. Clevudine is already approved for HBV in South Korea and the
Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under
the brand name Levovir. R7128, an oral treatment for chronic HCV infection,
has completed a 4-week clinical trial in combination with Pegasys(R) plus
Copegus(R) through a strategic collaboration with Roche. An IND for PSI-7851,
a second generation nucleotide HCV inhibitor was filed in January 2009.
Racivir, which is being developed for the treatment of HIV in combination with
other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: Statements in this press release regarding our business
that are not historical facts are "forward-looking statements" that involve
risks and uncertainties, including without limitation, the risk that adverse
events could cause the cessation or delay of any of the ongoing or planned
clinical trials and/or our development of our product candidates, the risk
that the results of previously conducted studies involving our product
candidates will not be repeated or observed in ongoing or future studies
involving our product candidates, the risk that our collaboration with Roche
will not continue or will not be successful and the risk that any one or more
of our product candidates will not be successfully developed and
commercialized. For a discussion of these risks and uncertainties, any of
which could cause our actual results to differ from those contained in the
forward-looking statements, see the section of our Annual Report on Form 10-K
for the fiscal year ended September 30, 2008 and our Quarterly Report on Form
10-Q for the period ended December 31, 2008 filed with the Securities and
Exchange Commission entitled "Risk Factors" and discussions of potential risks
and uncertainties in our subsequent filings with the Securities and Exchange
Commission.

SOURCE Pharmasset, Inc.

Richard E. T. Smith, Ph.D., VP, Investor Relations and Corporate
Communications, +1-609-613-4181, richard.smith@pharmasset.com